Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new - Université de Rennes Access content directly
Journal Articles International Journal of Antimicrobial Agents Year : 2017

Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new

Michael Z. David
  • Function : Author
Matthew Dryden
  • Function : Author
Thomas Gottlieb
  • Function : Author
Ian M. Gould
  • Function : Author

Abstract

A number of novel antimicrobial drugs with activity against Gram-positive bacterial pathogens have been licensed in the past 4 years. These drugs have the potential to enrich the group of intravenous drugs already available that are in common use against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci and other antibiotic-resistant Gram-positive pathogens. The advantages and disadvantages of these drugs are not yet fully appreciated. Here we review the five most promising newly approved compounds, namely ceftaroline, ceftobiprole, oritavancin, dalbavancin and tedizolid. The advantages of their dosing regimens, mechanisms of action and adverse effect profiles as well as evidence for their clinical usefulness and the unique characteristics that distinguish them from one another and from older drugs are reviewed.
Fichier principal
Vignette du fichier
David et al. - Recently approved antibacterials for MRSA and othe.pdf (800.67 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-01697318 , version 1 (31-01-2018)

Identifiers

Cite

Michael Z. David, Matthew Dryden, Thomas Gottlieb, Pierre Tattevin, Ian M. Gould. Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new. International Journal of Antimicrobial Agents, 2017, 50 (3), pp.303 - 307. ⟨10.1016/j.ijantimicag.2017.05.006⟩. ⟨hal-01697318⟩
965 View
643 Download

Altmetric

Share

Gmail Facebook X LinkedIn More